142 related articles for article (PubMed ID: 37463241)
1. Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma.
Chong PSY; Chooi JY; Lim JSL; Leow ACY; Toh SHM; Azaman I; Koh MY; Teoh PJ; Tan TZ; Chung TH; Chng WJ
Cancer Res; 2023 Oct; 83(20):3414-3427. PubMed ID: 37463241
[TBL] [Abstract][Full Text] [Related]
2. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
4. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
[TBL] [Abstract][Full Text] [Related]
5. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
Jiang H; Wang Y; Wang J; Wang Y; Wang S; He E; Guo J; Xie Y; Wang J; Li X; Peng Z; Wang M; Hou J; Liu Z
Clin Transl Med; 2022 Apr; 12(4):e744. PubMed ID: 35389552
[TBL] [Abstract][Full Text] [Related]
6. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
[TBL] [Abstract][Full Text] [Related]
7. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
Popovic R; Martinez-Garcia E; Giannopoulou EG; Zhang Q; Zhang Q; Ezponda T; Shah MY; Zheng Y; Will CM; Small EC; Hua Y; Bulic M; Jiang Y; Carrara M; Calogero RA; Kath WL; Kelleher NL; Wang JP; Elemento O; Licht JD
PLoS Genet; 2014 Sep; 10(9):e1004566. PubMed ID: 25188243
[TBL] [Abstract][Full Text] [Related]
8. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract][Full Text] [Related]
9. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
[TBL] [Abstract][Full Text] [Related]
10. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
[TBL] [Abstract][Full Text] [Related]
11. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
[TBL] [Abstract][Full Text] [Related]
13. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer.
Zhao LH; Li Q; Huang ZJ; Sun MX; Lu JJ; Zhang XH; Li G; Wu F
Cell Death Dis; 2021 Oct; 12(11):974. PubMed ID: 34671018
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma.
Ikeda S; Abe F; Matsuda Y; Kitadate A; Takahashi N; Tagawa H
Cancer Sci; 2020 Nov; 111(11):4088-4101. PubMed ID: 32790954
[TBL] [Abstract][Full Text] [Related]
15. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract][Full Text] [Related]
16. Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.
Zheng Y; Fornelli L; Compton PD; Sharma S; Canterbury J; Mullen C; Zabrouskov V; Fellers RT; Thomas PM; Licht JD; Senko MW; Kelleher NL
Mol Cell Proteomics; 2016 Mar; 15(3):776-90. PubMed ID: 26272979
[TBL] [Abstract][Full Text] [Related]
17. S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
Wang Q; Zheng J; Zou JX; Xu J; Han F; Xiang S; Liu P; Chen HW; Wang J
Chem Biol Interact; 2020 Feb; 317():108965. PubMed ID: 32001260
[TBL] [Abstract][Full Text] [Related]
18. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Ng YLD; Ramberger E; Bohl SR; Dolnik A; Steinebach C; Conrad T; Müller S; Popp O; Kull M; Haji M; Gütschow M; Döhner H; Walther W; Keller U; Bullinger L; Mertins P; Krönke J
Nat Commun; 2022 Feb; 13(1):1009. PubMed ID: 35197447
[TBL] [Abstract][Full Text] [Related]
19. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.
Hirano M; Imai Y; Kaito Y; Murayama T; Sato K; Ishida T; Yamamoto J; Ito T; Futami M; Ri M; Yasui H; Denda T; Tanaka Y; Ota Y; Nojima M; Kamikubo Y; Gotoh N; Iida S; Handa H; Tojo A
J Exp Clin Cancer Res; 2021 Mar; 40(1):110. PubMed ID: 33757580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]